Navigation Links
AMT CEO Ronald Lorijn Steps Down
Date:1/22/2009

AMSTERDAM, January 22 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that Dr. Ronald H.W. Lorijn will for personal reasons retire as chief executive officer, effective February 1, 2009. Prof. Sander van Deventer, AMT's chief scientific officer and co-founder of the company, has been named chief executive officer on an interim basis.

Since Ronald Lorijn started in 2005, AMT changed from a small, one-product company into a leading gene therapy company with a richly filled R&D pipeline and lead product Glybera(R). The Company reached within four years a number of key milestones: successful financing round in 2006; successful IPO in 2007; multiple R&D strategic international collaborations; and Glybera(R) close to filing for marketing approval in Europe, USA and Canada.

"Under Ronald's leadership the company has delivered outstanding results for which we are very grateful. We look forward to continuing the execution of the company strategy by building on this strong foundation," said Ferdinand Verdonck, chairman of the Supervisory Board.

"I regret that personal reasons prevent me from being actively involved in the next level of growth of AMT. I wish this great company and its people a lot of success in achieving the goal we have set ourselves: offering cures for patients suffering from serious, debilitating diseases by making gene therapy available to them", said Ronald Lorijn.

Sander van Deventer: "I look forward to guiding AMT at this important stage with the clinical trial for Glybera(R) and the filing of the marketing authorization dossier for this product. I am focused on successfully developing our drug candidates into cures for serious diseases together with the team of excellent and experienced people at our company."

Ferdinand Verdonck adds: "Sander van Deventer
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. [video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.nets 3-Minute Press Show
2. MiMedx Group, Inc. Adds Ronald G. Wallace to Board of Directors
3. Neurobiological Technologies, Inc. Reports Retirement of Ronald E. Cape, Ph.D., from Board
4. Jonathan Lewis, M.D., Ph.D. Steps Down From Delcath Systems Board of Directors
5. Graphene pioneers follow in Nobel footsteps
6. Pharmaxis First Steps into China
7. Three Steps to Boost Asymchems Investment in China
8. Survey of More than 600 Patients Treated with Tracleer(R) (bosentan) Reveals Actelion Sure Steps(R) Patient Support Program Provides Valuable Educational Information
9. New White Paper Details Six Steps to Investigate and Prevent Laboratory Accidents
10. Yale scientists make 2 giant steps in advancement of quantum computing
11. New Survey Reveals Many Adults With High Cholesterol Fail to Take Necessary Steps to Improve Their Condition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 16, 2014 “Never say, ‘I ... Universität Marburg’s Department of Physics, advises young women ... newly released SPIE Women in Optics 18-month ... shy to ask questions.” , In the annual ... mathematics) occupations ranging from university professor and laboratory ...
(Date:12/17/2014)... BASKING RIDGE, N.J. (PRWEB) December 17, 2014 ... Ipsen (Euronext: IPN; ADR: IPSEY), ... 120 mg (referred to as Somatuline®) was approved ... for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) ... differentiated, locally advanced or metastatic disease to improve ...
(Date:12/17/2014)... This report is a professional ... For an overview analysis, the report introduces quartz ... structure, industry overview, policy analysis, and news analysis, ... has witnessed rapid development with key manufacturers increasing ... report mentions quartz tubing upstream raw materials and ...
(Date:12/17/2014)... December 17, 2014 Gene synthesis ... it has entered into a technology access and ... to apply DNA2.0’s proprietary protein engineering technology, known ... , “We are extremely excited that the global ... This proprietary bioengineering technology has now been ...
Breaking Biology Technology:Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 2Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 82020 Quartz Tubing Market: Global Development & Forecasts Analysis Now at DeepResearchReports.com 2ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2
... /PRNewswire-FirstCall/ - Oncothyreon Inc. (NASDAQ: ONTY ) (TSX: ONY) ... basic and diluted share, for the three months ended June 30, ... per basic and diluted share, for the comparable period in 2008. ... months ended June 30, 2009 for the change in the fair ...
... , , , ... Accera, Inc., a biotechnology company delivering breakthrough therapies in central ... paper in the peer-reviewed journal Nutrition & Metabolism . ... mild to moderate Alzheimer,s disease: a randomized, double-blind, placebo-controlled, multicenter ...
... , , , ... Cempra Pharmaceuticals today announced the appointment of John H. ... of Eli Lilly and Company, to the company,s Board of ... executive and operational management experience, including leadership of successful anti-infective ...
Cached Biology Technology:Oncothyreon reports second quarter 2009 financial results 2Oncothyreon reports second quarter 2009 financial results 3Oncothyreon reports second quarter 2009 financial results 4Oncothyreon reports second quarter 2009 financial results 5Oncothyreon reports second quarter 2009 financial results 6Oncothyreon reports second quarter 2009 financial results 7Accera Announces Peer-Reviewed Publication of the Results of its 90-Day Clinical Study of AC-1202 (Axona(TM) ) in Mild to Moderate Alzheimer's Disease 2Accera Announces Peer-Reviewed Publication of the Results of its 90-Day Clinical Study of AC-1202 (Axona(TM) ) in Mild to Moderate Alzheimer's Disease 3Cempra Pharmaceuticals Announces Appointment of John H. Johnson to Board of Directors 2Cempra Pharmaceuticals Announces Appointment of John H. Johnson to Board of Directors 3
(Date:12/11/2014)... 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of ... report to their offering. One ... adoption of multimodal biometric systems. Multimodal biometric systems ... for verification and identification purposes. This helps to ...
(Date:12/10/2014)... , Dec. 8, 2014 You,ve been here before: ... but can,t remember your password, site key or the answer ... your first grade teacher? Today, Hoyos ... app that will finally put an end to the ... 1U TM . 1U leverages a user,s smartphone to ...
(Date:12/10/2014)... 2014 CIE San Diego has launched an ... connective tissue that enhances care coordination among social service ... client-level information; earned a second $1 million grant from ... seniors aging in community and; will be recognized as ... th 4-6p. CIE San Diego today ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
... Materials engineers have created a new type of membrane ... be used for environmental cleanup, water purification and industrial ... conventional filters for separating oil from water and works ... usually mutually exclusive. Researchers attached the material to a ...
... the Netherlands Royal Academy of Arts and Sciences (KNAW) ... a new research programme: the Joint Scientific Thematic Research ... and the Academy will work together on developing bilateral ... and the Academy launched the joint research programme during ...
... Journal of Preventive Medicine special issue on climate ... Climate Changing People" conference today in Los Angeles. ... MD, DrPH, speaking about the impacts of climate change ... public health challenge. Health professionals need to understand the ...
Cached Biology News:New filtering technology has environmental, industrial applications 2New filtering technology has environmental, industrial applications 3NWO and Academy launch research program with China 2Issues at intersection of climate change and health impact global well-being 2Issues at intersection of climate change and health impact global well-being 3Issues at intersection of climate change and health impact global well-being 4
... arrays have been developed for affinity ... A variety of ProteinChip chemical surfaces ... to their unique biochemical properties. Each ... side-by-side sample comparison, and the chips ...
... been developed for affinity capture of ... of ProteinChip chemical surfaces allow differential ... unique biochemical properties. Each chip has ... comparison, and the chips are color-coded ...
... have been developed for affinity capture ... variety of ProteinChip chemical surfaces allow ... their unique biochemical properties. Each chip ... sample comparison, and the chips are ...
... Gel extraction kit, 100 preps Storage: The kit ... For longer storage, keep all contents of the ... column purification kit utilizes a silica-gel based membrane ... fragments in the presence of specialized binding buffers. ...
Biology Products: